UT · State regulatory reference

Utah.

Moderate

Utah's Telehealth Act (Utah Code § 26B-4-704, amended 2023; rule R156-1-602) is relatively permissive — it defines synchronous audio-video interaction and lets a provider establish the provider-patient relationship during the encounter, so an initial visit plus prescribing can occur via telehealth. Compounding follows federal 503A with USP <795>/<797>/<800> adopted. The Board of Pharmacy has reported (May 2024 Board newsletter) that DOPL issued citations around compounded semaglutide — targeting unlicensed med spas dispensing it in syringes, out-of-scope dispensing, salt forms, and 503A office-use — but these enforce federal and scope-of-practice baselines rather than a distinctive Utah rule, and the Board's 2025 posture was to monitor FDA. No primary-sourced named enforcement order was found.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Utah Medical Board

https://dopl.utah.gov/medicine/ ↗

Pharmacy board

Utah Board of Pharmacy

https://dopl.utah.gov/pharmacy/ ↗

TPC notes

Telehealth

Utah Code § 26B-4-704 permits telehealth via synchronous two-way audio-video and allows the provider-patient relationship to be established during the encounter; before prescribing, the provider must obtain and document relevant clinical history and symptoms, establish a diagnosis, and identify contraindications (R156-1-602 adds identity-verification and informed-consent duties).

Compounding

Utah follows federal 503A and has adopted USP <795>/<797>/<800>; the Board's May 2024 newsletter reports DOPL citations around compounded semaglutide (salt forms, medical-spa and out-of-scope dispensing, 503A office-use), reflecting enforcement of federal and scope baselines rather than a distinctive statutory GLP-1 ban.

Sources